Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous tissue-engineered skin substitute for reconstruction after Mohs surgery in basal cell carcinoma
2024-515235-29-00Phase 2Authorised
- Sponsor
- Red Andaluza de Terapias Avanzadas
- Start
- Jul 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous skin-derived adult keratinocyte and fibroblast cell sheet (fibrin-agarose matrix) in basal cell carcinoma (BCC) (3 arms), sponsored by Red Andaluza de Terapias Avanzadas. Primary endpoints: Safety and Feasibility. Planned start Jul 2024; status: authorised.
02
Drugs
autologous skin-derived adult keratinocyte and fibroblast cell sheet (fibrin-agarose matrix)
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2024-515235-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515235-29-00.